Synapse - Craig Moskowitz

Results (93)

Relapsed and primary refractory diffuse large cell lymphoma (DLCL) salvaged with involved field radiotherapy (IFRT) & high dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT)

Meeting Abstract

Hoppe, B. S.; Moskowitz, C. H.; Moskowitz, C. S.; Filippa, D. A.; Kewalramani, T.; Yahalom, J.
International Journal of Radiation Oncology, Biology, Physics (2007)

Fulltext@MSK | Save

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma

Journal Article

O'Connor, O. A.; Hamlin, P. A.; Portlock, C.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Macgregor-Cortelli, B.; Neylon, E.; Sarasohn, D.; Dumetrescu, O.; more...
British Journal of Haematology (2007)

Fulltext@MSK | Save

Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-Cell lymphomas: Results of the MSKCC phase I/II experience

Meeting Abstract

O'Connor, O. A.; Hamlin, P. A.; Gerecitano, J.; Portlock, C. S.; Noy, A.; Moskowitz, C.; Straus, D. J.; Sarasohn, D.; Dumitrescu, O.; Pappanicholaou, J.; more...
Blood (2006)

Fulltext@MSK | Save

Early phase experience with pralatrexate (10-propargyl-10-deazaaminopterin [PRX]), a novel antifolate with high affinity for the reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies

Meeting Abstract

O'connor, O.; Hamlin, P.; Neylon, E.; Moskowitz, C.; Portlock, C.; Noy, A.; Sirotnak, F.; Zelenetz, A.; Mould, D.; Horwitz, S.
EJC Supplements (2006)

Fulltext@MSK | Save

Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL

Meeting Abstract

Moskowitz, C.; Hamlin, P. A.; Horwitz, S. M.; Noy, A.; O'Connor, O. A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Lessac-Chenen, S.; Weaver, A.; more...
Blood (2006)

Fulltext@MSK | Save

FDG-PET scans as a staging study for T-cell lymphomas: High rates of positivity do not result in frequent changes in stage

Meeting Abstract

Horwitz, S. M.; Foss, F.; Goldfarb, S.; Molina, A.; Hamlin, P. A.; O'Connor, O. A.; Cammarata, M.; Moskowitz, C. H.; Zelenetz, A. D.
Blood (2006)

Fulltext@MSK | Save

Relapsed and refractory primary mediastinal diffuse large B-cell lymphoma: Outcome with ICE-based treatment

Meeting Abstract

Hamlin, P. A.; Dickson, M.; Kewalramani, T.; Horwitz, S. M.; Portlock, C. S.; Yahalom, J.; Zelenetz, A. D.; Moskowitz, C. H.
Blood (2006)

Fulltext@MSK | Save

The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed/refractory indolent B-cell lymphomproliferative disorders

Meeting Abstract

Gerecitano, J.; Portlock, C.; Noy, A.; Hamlin, P.; Moskowitz, C.; Straus, D.; Horwitz, S. M.; Palomba, M. L.; Dumitrescu, O. L.; Pappanicholaou, J.; more...
Blood (2006)

Fulltext@MSK | Save

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

Journal Article

O'Connor, O. A.; Heaney, M. L.; Schwartz, L.; Richardson, S.; Willim, R.; Macgregor-Cortelli, B.; Curly, T.; Moskowitz, C.; Portlock, C.; Horwitz, S.; more...
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma

Journal Article

Kewalramani, T.; Zelenetz, A. D.; Teruya-Feldstein, J.; Hamlin, P.; Yahalom, J.; Horwitz, S.; Nimer, S. D.; Moskowitz, C. H.
British Journal of Haematology (2006)

Fulltext@MSK | Save